At one year, the drug met its primary and all key secondary endpoints, delivering significantly better weight maintenance than placebo
The drug, intended for chronic weight management alongside diet and exercise, is now under the FDA’s new CNPV expedited review pathway
The trial tested six injectable doses and three oral doses over as long as 36 weeks
The formulation is backed by over 80 clinical trials and 200 scientific publications
Roche will unveil the primary results from the phase III evERA Breast Cancer study evaluating giredestrant
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
Tegoprazan, a novel patented molecule indicated for acid-related gastrointestinal diseases, is launched in India under the brand name PCAB
Ascletis announces ultra-long-acting subcutaneous depot maintenance formulation of small molecule GLP-1R agonist ASC30 with 75-Day observed half-life in participants with obesity
Cagrilintide represents a novel approach to obesity management
Subscribe To Our Newsletter & Stay Updated
